歐林生物(688319.SH):2022年度淨利潤預降74.99%到79.62%
格隆匯1月28日丨歐林生物(688319.SH)公佈,預計2022年年度實現營業收入為人民幣5.3億元至5.5億元,較上年同期相比,將增加4284.84萬元至6284.84萬元,同比增長8.80%至12.90%。
預計2022年年度實現歸屬於母公司所有者的淨利潤為2200萬元到2700萬元,與上年同期相比,預計減少8096.35萬元到8596.35萬元,同比下降74.99%到79.62%。
預計2022年年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為-385萬元到115萬元,與上年同期相比,預計減少9551.01萬元到10051.01萬元,同比下降98.81%到103.98%。
2022年度,公司穩步推進各項業務,營業收入較上年同期有所增長。淨利潤減少的主要原因如下:
1、報吿期內,為推進中長期產品研發戰略、提高公司市場競爭力,公司加大了對在研項目和儲備項目的研發投入,新增細胞基質流感疫苗等疫苗管線,並積極引入各類生物資源,導致本期費用化研發支出約為12300萬元,較上年同期增加約6600萬元。
2、報吿期內,公司所得税費用比上年同期增加約1800萬元,主要原因系公司2021年仍處於彌補虧損狀態,所得税費用為負;2022年預計發生所得税費用約1700萬元,導致所得税費用絕對值大幅增加。
3、報吿期內,公司資產減值損失比上年同期增加約500萬元,主要原因系根據會計準則,對近效期的存貨計提減值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.